Check out our News below.

Servier and Ipsen Join Access Accelerated to Fight Growing NCD Burden

Two global biopharmaceutical companies join effort to address the growing non-communicable disease burden in low- and middle-income countries

GENEVA, SWITZERLAND – Today, Ipsen and Servier, two global biopharmaceutical companies, joined Access Accelerated, an initiative aimed at advancing access to non-communicable disease (NCD) prevention, treatment and care in low- and middle income countries (LMICs). Together with partners from across the global biopharmaceutical sector, multilateral organizations and non-governmental organizations, Access Accelerated works toward a future where no one dies prematurely from treatable, preventable diseases.

NCDs are responsible for 71 percent of global deaths annually and 15 million people who die from an NCD are between the ages of 30 and 69 years. An alarming 85 percent of these premature deaths occur in LMICs[1].  Health systems in LMICs are often not optimised to address this growing burden and people face multiple barriers to prevention, treatment and care.

Now consisting of more than 25 biopharmaceutical companies, Access Accelerated unites industry action and applies member companies’ global reach and local expertise to address the NCD burden. By working with partners to co-create scalable and sustainable solutions, the initiative supports inclusive local and country-led engagement and ownership. Both Servier and Ipsen have embraced the Access Accelerated commitment to achieve the United Nations Sustainable Development Goals (SDGs), particularly, target 3.4 to reduce premature deaths from NCDs by one-third by 2030.

Ipsen, based in Paris, France, aims to improve lives through innovative medicines in oncology, neuroscience and rare diseases. Ipsen sells more than 20 medicines in 115 countries and has over 5,700 employees worldwide.

“Knowing that patients don’t have time to wait, Ipsen is delighted to team up with Access Accelerated. To benefit patients around the world, we’ll leverage our legacy and strong expertise to support better access to treatment and care.” said Dominique Laymand, Ipsen’s Executive Vice President, Ethics and Social Responsibility Chief Officer.

Servier is an international pharmaceutical company, headquartered in France, committed to providing accessible quality healthcare to patients. Operating in 149 countries, Servier is focused on five major areas: cardiovascular, immune-inflammatory and neurodegenerative diseases, cancer and diabetes.

 “Servier is dedicated to therapeutic progress to serve patient needs. We have a social responsibility to improve access to health for patients. Servier’s participation to Access Accelerated will support this everyday commitment,” said Vincent Minvielle, Head of Servier Corporate Social Responsibility.

Access Accelerated Director James Pfitzer said, “Servier and Ipsen bring a wealth of knowledge and expertise in NCD care and we are delighted for both companies to join Access Accelerated. Their contributions will further bolster our efforts to combat the global NCD crisis and end premature deaths from preventable, treatable diseases.”

About Access Accelerated

Access Accelerated is a global partnership of more than 25 biopharmaceutical companies aimed at addressing the growing NCD health challenge. Using a multi-sectoral approach, Access Accelerated develops, measures, and replicates sustainable programs in low- and middle income countries to advance access to NCD prevention and care. For more information about Access Accelerated visit:

About Ipsen

Ipsen is a global specialty-driven biopharmaceutical group focused on innovation and specialty care. The group develops and commercializes innovative medicines in three key therapeutic areas – Oncology, Neuroscience and Rare Diseases. Its commitment to Oncology is exemplified through its growing portfolio of key therapies for prostate cancer, neuroendocrine tumors, renal cell carcinoma and pancreatic cancer. Ipsen also has a well-established Consumer Healthcare business. With total sales over €2.2 billion in 2018, Ipsen sells more than 20 drugs in over 115 countries, with a direct commercial presence in more than 30 countries. Ipsen’s R&D is focused on its innovative and differentiated technological platforms located in the heart of the leading biotechnological and life sciences hubs (Paris-Saclay, France; Oxford, UK; Cambridge, US). The Group has about 5,700 employees worldwide. Ipsen is listed in Paris (Euronext: IPN) and in the United States through a Sponsored Level I American Depositary Receipt program (ADR: IPSEY). For more information on Ipsen, visit:

About Servier

Servier is an international pharmaceutical company governed by a non-profit foundation, with its headquarters in France (Suresnes). With a strong international presence in 149 countries and a turnover of 4.2 billion euros  in 2018, Servier employs 22,000 people worldwide. Entirely independent, the Group reinvests 25% of its turnover (excluding generics) in research and development and uses all its profits for development. Corporate growth is driven by Servier’s constant search for innovation in five areas of excellence: cardiovascular, cancer and metabolism, immune-inflammatory and neurodegenerative diseases, as well as by its activities in high-quality generic drugs. Servier also offers eHealth solutions beyond drug development. For more information on Servier, visit:


Stacy Montejo
+1 202-585-2025

[1] World Health Organization, Noncommunicable Diseases Fact Sheet. 1 June 2018.


IFPMA (“we”, “us”) owns and operates (“the/our website”). Any person accessing and/or using the website (“the visitor/user”) agrees to the “Terms of Use”, containing the conditions, rules and other provisions with respect to the access and/or use of our website. If you have questions about the “Terms of Use”, please feel free to contact us at


General Use

The material contained on this website is for information only. The website is entitled to be served as an information resource for the internal and external stakeholders of IFPMA, including the general public. Third-Party Websites Links to other websites are provided solely as a convenience and therefore imply neither IFPMA’s responsibility for, nor its approval of the information contained in these websites. Intellectual Property Any use of information from the website should have an acknowledgement of IFPMA/Third-Party as a source respectively, citing the corresponding uniform resource locator (URL). Logo and Name The use of IFPMA’s name and/or logo is prohibited without prior express authorization from IFPMA. The access and/or use of the website does not permit to copy, reproduce, modify, distribute or elsehow exploit IFPMA’s name and/or logo except with the prior explicit permission. Abuse and Violation Any abuse or violations of the Terms of Use and/or Privacy Policy should be reported to


IFPMA renounces any liability or responsibility for any damages of any nature whatsoever resulting from the use of, inability to use, and/or reliance on the material and information contained on our website. IFPMA makes no representations or warranties as to the completeness or accuracy of any of the information available on the website as well as does not provide any warranties regarding the security of the content of our website or any linked websites. IFPMA endeavours to make its best effort to keep the information accurate and updated on a regular basis, however this is not claimed to be exhaustive. IFPMA does not guarantee that the website is continuously available and error-free at all times.

Privacy Policy

IFPMA is committed to protecting the privacy and security of visitors to our website. Outlined below is our online privacy policy for information collected through our website. If you have questions about these policies, please feel free to contact us at

Personal Information

We constantly analyse our website logs to improve the value of our website. We do not use this analysis to record or track any personally identifiable information of our visitors. If you are asked to provide personal information such as your name, e-mail or/and postal address when requesting information, providing feedback, registering to a newsletter, or using any other functions of the website, be assured that all such information is considered by IFPMA both private and secure. IFPMA does not share or sell your personal information to third parties. Under no circumstance will details be disclosed publicly, except in order to comply with any legal obligation. This policy reiterates that IFPMA fully appreciates the importance of online privacy and is committed to protecting your personal information.

Use of Cookies Files

Our website is enhanced by cookie files to personalize and customize the experience of our visitors and to support some necessary functions. IFPMA collects broad usage statistics using Google Analytics, to better understand how our visitors use our website, and to help us improve visitors’ experience. Such information includes the IP address (where available), browser type, and any additional information provided by a browser during the use of our website. The statistical data about our users’ browsing actions and patterns does not identify any individual. You may choose to accept or refuse cookies by modifying your browser preferences. If you wish to get notified when a cookies are set, this option should also be available in your browser settings. Please note that if you reject some or all cookies, your experience at this and other websites throughout the Internet may not be complete.

Payment Transactions

To enable IFPMA to process any order or registration to an event, a secure online payment system may be used to process payments using credit card details. IFPMA will not be collecting or storing credit card details in our system.

Third-Party Websites

Please be aware that other websites to which links may be provided, including social media, may collect visitor’s personally identifiable information when accessed. The information collection practices of other websites linked to IFPMA’s website are not covered by this Privacy Policy.

This website uses cookies to ensure you get the best experience on our website. Learn More